Luca Benatti - Net Worth and Insider Trading

Luca Benatti Net Worth

The estimated net worth of Luca Benatti is at least $92,561 dollars as of 2023-06-09. Luca Benatti is the Director of Intercept Pharmaceuticals Inc and owns about 7,556 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $92,561. Details can be seen in Luca Benatti's Latest Holdings Summary section.

Transaction Summary of Luca Benatti


Luca Benatti Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Luca Benatti owns 1 companies in total, including Intercept Pharmaceuticals Inc (ICPT) .

Click here to see the complete history of Luca Benatti’s form 4 insider trades.

Insider Ownership Summary of Luca Benatti

Ticker Comapny Transaction Date Type of Owner
ICPT Intercept Pharmaceuticals Inc 2020-05-28 director

Luca Benatti Latest Holdings Summary

Luca Benatti currently owns a total of 1 stock. Luca Benatti owns 7,556 shares of Intercept Pharmaceuticals Inc (ICPT) as of May 14, 2019, with a value of $92,561.

Latest Holdings of Luca Benatti

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ICPT Intercept Pharmaceuticals Inc 2019-05-14 7,556 12.25 92,561

Holding Weightings of Luca Benatti

Luca Benatti Form 4 Trading Tracker

According to the SEC Form 4 filings, Luca Benatti has made a total of 1 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Intercept Pharmaceuticals Inc is the acquisition of 1,200 shares on May 14, 2019, which cost Luca Benatti around $100,200.

Insider Trading History of Luca Benatti

Insider Trading Shares
Shares Change
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
Intercept Pharmaceuticals Inc
Total 1
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Luca Benatti Trading Performance

GuruFocus tracks the stock performance after each of Luca Benatti's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Luca Benatti is -24.55%. GuruFocus also compares Luca Benatti's trading performance to market benchmark return within the same time period. The performance of stocks bought by Luca Benatti within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Luca Benatti's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Luca Benatti

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) -8.33 -24.55 -4.27 -4.56 -54.21 -40.93
Relative Return to S&P 500(%) -10.18 -24.77 -13.52 -5.2 -75.53 -53.32

Luca Benatti Ownership Network

Ownership Network List of Luca Benatti

No Data

Ownership Network Relation of Luca Benatti

Luca Benatti Owned Company Details

What does Intercept Pharmaceuticals Inc do?

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Who are the key executives at Intercept Pharmaceuticals Inc?

Luca Benatti is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.


Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

Luca Benatti Mailing Address

Above is the net worth, insider trading, and ownership report for Luca Benatti. You might contact Luca Benatti via mailing address: C/o Intercept Pharmaceuticals, Inc., 450 West 15th Street, Suite 505, New York Ny 10011.